Literature DB >> 23602523

The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.

Xuan Zhang1, Jie Zhang, Linjiang Tong, Yu Luo, Mingbo Su, Yi Zang, Jia Li, Wei Lu, Yi Chen.   

Abstract

A novel class of colchicine-SAHA hybrids were designed and synthesised based on the synergistic antitumor effect of tubulin inhibitors and histone deacetylases (HDAC) inhibitors. To the best of our knowledge, this is the first design of molecules that are dual inhibitors of tubulin and HDAC. Biological evaluations of these compounds included the inhibitory activity of HDAC, in vitro cell cycle analysis in BEL-7402 cells as well as cytotoxicity in five cancer cell lines.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23602523     DOI： 10.1016/j.bmc.2013.03.049

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN： 0968-0896            Impact factor:   3.641


  9 in total

1.  A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.

Authors:  Stefanie Galbán; April A Apfelbaum; Carlos Espinoza; Kevin Heist; Henry Haley; Karan Bedi; Mats Ljungman; Craig J Galbán; Gary D Luker; Marcian Van Dort; Brian D Ross
Journal:  Mol Cancer Ther       Date:  2017-08-03       Impact factor: 6.261

2.  Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.

Authors:  Shipeng He; Guoqiang Dong; Zhibin Wang; Wei Chen; Yahui Huang; Zhengang Li; Yan Jiang; Na Liu; Jianzhong Yao; Zhenyuan Miao; Wannian Zhang; Chunquan Sheng
Journal:  ACS Med Chem Lett       Date:  2015-01-14       Impact factor: 4.345

3.  Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.

Authors:  Marcian E Van Dort; Stefanie Galbán; Hanxiao Wang; Judith Sebolt-Leopold; Christopher Whitehead; Hao Hong; Alnawaz Rehemtulla; Brian D Ross
Journal:  Bioorg Med Chem       Date:  2015-03-06       Impact factor: 3.641

4.  Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).

Authors:  Marcian E Van Dort; Hao Hong; Hanxiao Wang; Charles A Nino; Rachel L Lombardi; Avery E Blanks; Stefanie Galbán; Brian D Ross
Journal:  J Med Chem       Date:  2016-03-15       Impact factor: 7.446

5.  Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.

Authors:  Ji Liu; Tingting Wang; Xinyang Wang; Lin Luo; Jing Guo; Yanfu Peng; Qibing Xu; Jiefei Miao; Yanan Zhang; Yong Ling
Journal:  Medchemcomm       Date:  2017-03-29       Impact factor: 3.597

6.  SAHAquines, Novel Hybrids Based on SAHA and Primaquine Motifs, as Potential Cytostatic and Antiplasmodial Agents.

Authors:  Maja Beus; Zrinka Rajić; Dusica Maysinger; Zvonimir Mlinarić; Maja Antunović; Inga Marijanović; Diana Fontinha; Miguel Prudêncio; Jana Held; Sureyya Olgen; Branka Zorc
Journal:  ChemistryOpen       Date:  2018-08-21       Impact factor: 2.911

Review 7.  Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.

Authors:  Muhammad Nadeem Abbas; Saima Kausar; Feng Wang; Yongju Zhao; Hongjuan Cui
Journal:  Cells       Date:  2019-04-12       Impact factor: 6.600

8.  Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule.

Authors:  Issan Zhang; Maja Beus; Ursula Stochaj; Phuong Uyen Le; Branka Zorc; Zrinka Rajić; Kevin Petrecca; Dusica Maysinger
Journal:  Cell Death Discov       Date:  2018-09-26

Review 9.  Bifunctional HDAC Therapeutics: One Drug to Rule Them All?

Authors:  Joshua P Smalley; Shaun M Cowley; James T Hodgkinson
Journal:  Molecules       Date:  2020-09-24       Impact factor: 4.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.